Hypothesis

Individuals with a blunted circadian rhythm of pain sensitivity—defined as reduced amplitude between nocturnal peak and diurnal trough—exhibit accelerated epigenetic aging independent of their average pain threshold.

Mechanistic Rationale

Pain sensitivity oscillates under circadian control, with roughly 80% of daily variation driven by the core clock machinery (BMAL1, PER, CRY, CLOCK) that modulates spinal dopaminergic signaling [3, 4]. Clock‑gene expression also regulates mitochondrial ROS production and vagal afferent tone, both of which influence inflammaging and epigenetic clock rates [5]. When circadian robustness wanes, the normal anti‑inflammatory peak in vagal activity during the early afternoon diminishes, allowing low‑grade inflammation to persist. This persistent inflammatory milieu drives DNA‑methylation changes captured by Horvath, PhenoAge, and GrimAge clocks. Thus, the shape of the pain‑sensitivity curve, not just its midline, reflects underlying mitochondrial‑vagal‑immune coupling that tracks biological age.

Testable Predictions

1. Across a healthy adult cohort, the amplitude of the 24‑hour pain‑sensitivity rhythm (measured via repeated heat‑pain thresholds) will correlate negatively with epigenetic age acceleration (r ≈ –0.4 to –0.6) after adjusting for chronological age, baseline pain threshold, and sleep duration.
2. Experimental dampening of circadian amplitude—forced desynchrony via shift‑light protocols—will produce a measurable increase in epigenetic age acceleration markers after one week, whereas enhancing amplitude through timed bright‑light exposure or melatonin administration will attenuate acceleration.
3. Pharmacological blockade of spinal dopamine D2 receptors will flatten the pain‑sensitivity rhythm without changing mean threshold, and this manipulation will correlate with increased plasma IL‑6 and decreased heart‑rate‑variability‑derived vagal index.

Experimental Design

• Participants: 120 adults aged 30–60, stratified by sex and BMI, free of chronic pain or neurodegenerative disease.
• Baseline: Collect blood for epigenetic clocks (Horvath, PhenoAge, GrimAge), quantify mean heat‑pain threshold (single session), and record 24‑hour pain‑sensitivity profile (hourly thresholds from 08:00 to 08:00 next day). Compute amplitude as (night‑peak – day‑trough).
• Intervention (crossover, washout 2 weeks): a. Circadian disruption: Exposure to intermittent bright light (≥1000 lux) during night hours for three consecutive nights to flatten the rhythm. b. Circadian reinforcement: Daily 30‑minute bright‑light pulse at 07:30 h plus 0.5 mg melatonin at 21:00 h for three days to amplify the rhythm.
• Outcomes: Post‑intervention 24‑hour pain‑sensitivity profiling, repeat epigenetic clock analysis, plasma cytokines (IL‑6, TNF‑α), and vagal tone (RMSSD from ECG).
• Analysis: Mixed‑effects models testing interaction between condition (disruption vs reinforcement) and change in amplitude predicting change in epigenetic age acceleration, controlling for baseline values.

If the hypothesis holds, pain‑sensitivity amplitude could serve as a low‑cost, real‑time readout of circadian‑mitochondrial‑vagal health, offering a functional complement to static methylation clocks and opening avenues for chronotherapeutic interventions to slow biological aging.